JP2022540890A5 - - Google Patents

Info

Publication number
JP2022540890A5
JP2022540890A5 JP2022502302A JP2022502302A JP2022540890A5 JP 2022540890 A5 JP2022540890 A5 JP 2022540890A5 JP 2022502302 A JP2022502302 A JP 2022502302A JP 2022502302 A JP2022502302 A JP 2022502302A JP 2022540890 A5 JP2022540890 A5 JP 2022540890A5
Authority
JP
Japan
Prior art keywords
optionally substituted
independently
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502302A
Other languages
English (en)
Japanese (ja)
Other versions
JP7557522B2 (ja
JP2022540890A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042183 external-priority patent/WO2021011689A1/en
Publication of JP2022540890A publication Critical patent/JP2022540890A/ja
Publication of JP2022540890A5 publication Critical patent/JP2022540890A5/ja
Application granted granted Critical
Publication of JP7557522B2 publication Critical patent/JP7557522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502302A 2019-07-16 2020-07-15 Cd73阻害剤 Active JP7557522B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962874533P 2019-07-16 2019-07-16
US62/874,533 2019-07-16
US201962927974P 2019-10-30 2019-10-30
US62/927,974 2019-10-30
US202062987653P 2020-03-10 2020-03-10
US62/987,653 2020-03-10
US202063049927P 2020-07-09 2020-07-09
US63/049,927 2020-07-09
PCT/US2020/042183 WO2021011689A1 (en) 2019-07-16 2020-07-15 Cd73 inhibitors

Publications (3)

Publication Number Publication Date
JP2022540890A JP2022540890A (ja) 2022-09-20
JP2022540890A5 true JP2022540890A5 (cg-RX-API-DMAC10.html) 2023-05-12
JP7557522B2 JP7557522B2 (ja) 2024-09-27

Family

ID=74209960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502302A Active JP7557522B2 (ja) 2019-07-16 2020-07-15 Cd73阻害剤

Country Status (4)

Country Link
US (1) US12544391B2 (cg-RX-API-DMAC10.html)
EP (1) EP3999517A4 (cg-RX-API-DMAC10.html)
JP (1) JP7557522B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021011689A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2025096605A1 (en) * 2023-10-31 2025-05-08 Oric Pharmaceuticals, Inc. Cd73 inhibitor and anti-cd38 agent combination therapy
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118359622B (zh) * 2024-04-16 2025-08-26 上海陶术生物科技股份有限公司 加利司伟中间体的制备方法
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
CN119552122B (zh) * 2025-01-27 2025-05-09 北京悦康科创医药科技股份有限公司 5'-磷酸酯修饰核苷及其制备方法与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) * 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂

Similar Documents

Publication Publication Date Title
RU2748731C2 (ru) Комбинация, содержащая антагонист ep4 и ингибитор иммунных контрольных точек
ES2764548T3 (es) Procedimientos de preparación de derivados de benzodiazepina citotóxicos
US6194579B1 (en) Highly lipophilic camptothecin derivatives
CN111295384A (zh) 双环类衍生物抑制剂、其制备方法和应用
EP3856345A1 (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP2024545233A5 (cg-RX-API-DMAC10.html)
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2021534108A5 (cg-RX-API-DMAC10.html)
MXPA01009081A (es) Derivados de campotecina que tienen actividad anti-tumoral.
JP2009534358A5 (cg-RX-API-DMAC10.html)
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
JP2006509842A5 (cg-RX-API-DMAC10.html)
JP2022539256A5 (cg-RX-API-DMAC10.html)
JP2022553702A5 (cg-RX-API-DMAC10.html)
JP2023533203A5 (cg-RX-API-DMAC10.html)
JP2023542065A5 (cg-RX-API-DMAC10.html)
JP2020511547A5 (cg-RX-API-DMAC10.html)
JP2024523422A5 (cg-RX-API-DMAC10.html)
JP2006514960A5 (cg-RX-API-DMAC10.html)
HUP0103937A2 (hu) Izoszorbid-mononitrát-származékok és alkalmazásuk csökkentett toleranciával járó értágítószerekként
JP2023515565A5 (cg-RX-API-DMAC10.html)
KR102432263B1 (ko) 사이클릭뎁시펩타이드의 제조 방법
RU2007147346A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
IL316674A (en) History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses
RU2007126746A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ